Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III avelumab vs docetaxel in PD-L1 positive NSCLC after platinum failure
2014-005060-15Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Overall survival time. Started Apr 2015; status: completed.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-005060-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005060-15.